Skip to content

No Operation After Short Course Radiotherapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer

No Operation After Short Course Equivalent Dose (Ht) Radiation Therapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer: The Prospective, Single Arm NOAHS-ARC Trial

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04864067
Acronym
NOAHS-ARC
Enrollment
39
Registered
2021-04-28
Start date
2021-06-09
Completion date
2026-05-05
Last updated
2026-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal Cancer

Keywords

Rectal Cancer, Radiotherapy, Neoadjuvant therapy, Adenocarcinoma

Brief summary

This study is designed to explore the hypothesis that in patients with a Locally advanced rectal cancer (LARC) treated with a Total neoadjuvant therapy (TNT) strategy based on short course radiotherapy (5x5Gy) followed by neoadjuvant consolidation chemotherapy is associated with a higher rate of pathological clinical response and sustained (\>1year) complete clinical response when compared to an historical cohort treated with long course chemoradiation therapy (CRT), total mesorectal excision (TME) and adjuvant chemotherapy (ACT).

Detailed description

Non-operative management with a Watch and Wait (W&W) strategy has been advocated for selected patients with a locally advanced rectal cancer (LARC) and a complete clinical response (cCR) after neoajuvant (NA) treatment. In this context, total neoadjuvant therapy (TNT), i.e the use of radiotherapy and full dose of post-operative chemotherapy as part of NA treatment, has emerged as a strategy to enhance treatment response. Currently, TNT has reported higher rates of pCR and organ preservation when compared to current standard of care. However, the best TNT strategy is still unknown. We therefore hypothesize that in LARC patients, the use of a TNT strategy based on short course RT followed by consolidation chemotherapy is associated with a higher rate of pCR and sustained (\>1year) cCR when compared to an historic cohort. The main aim of the present proposal is to assess the effects of a standardized TNT model in LARC patients as a strategy for enhanced pCR/sustained cCR. For this purpose, we propose the following experimental model: In primary Aim 1 we will study if the effects of a TNT strategy over patients with a LARC enhance the rate of pCR/sustained cCR by (1) evaluating the compliance and toxicity of a TNT strategy as a proof of concept of its applicability, (2) assessing the rate of cCR at the end of TNT and (3) assessing the rate of pCR in the surgically managed subgroup and sustained cCR (\>1year) in the W&W subgroup. Additionally, in primary Aim 2, we will determine if patients with a W&W strategy have better functional outcomes and quality of life (QoL) than patients treated with TME after TNT by (1) using validated questionnaires for the evaluation of bowel, sexual and urinary function for W&W and TME patients and (2) by evaluating the QoL using a widely-used standardized questionnaire.

Interventions

DRUGOxaliplatin

Consolidation Chemotherapy

DRUG5-Fluoracil

Consolidation Chemotherapy

DRUGLeucovorin

Consolidation Chemotherapy

DRUGCapecitabine

Consolidation Chemotherapy

RADIATION5x5 Gy

Neoadjuvant Radiotherapy

BEHAVIORALQuality of Life Questionnaires

Quality of Life Evaluation (LARS Score, IIEF, FSFI, I-PSS and EORTC QLQ-C30)

PROCEDUREDRE/ Endoscopy

Flexible Sigmoidoscopy and Digital Rectal Exam

Sponsors

Servicio de Salud Metropolitano Sur Oriente
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

The study was designed as a single-arm phase II trial with complete response as the primary endpoint - the composite of pCR after surgery and sustained cCR (≥1 year) during watch-and-wait surveillance. The null hypothesis was a local historical pCR rate of 12% after neoadjuvant chemoradiotherapy plus TME. Assuming an expected complete response rate of 30%, 48 evaluable patients were required for 80% power at a one-sided α of 0.05. A protocol amendment was approved by the Ethics Committee before any interim data were reviewed. It introduced two statistical refinements: a formalized interim analysis using Lan-DeMets α-spending with O'Brien-Fleming boundaries (early efficacy: ≥9/24 responders or p\<.006), and a futility stopping rule to protect patients from a non-beneficial regimen. No changes were made to the endpoint, eligibility, treatment, or follow-up. All amendments were Ethics Committee-approved before investigators reviewed any unblinded data.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Histologically confirmed diagnosis of adenocarcinoma of the rectum * Clinical Stage II (T3-4, N-) or Stage III (any T, N+) based on Magnetic Resonance Imaging (MRI) * Tumors \< 7cm from anal verge (palpable) * No prior history of rectal cancer

Exclusion criteria

* Patients with tumors \>7cm from anal verge * ECOG \>1, * Contraindication for chemotherapy: Hemoglobin \<8, White Blood Count \<4000, Platelets \<100,000, Creatinine Clearance \<50ml/min, Total Bilirubin \<5mg/dl, * Stage IV at diagnosis * Coronary artery disease, either no treated or recent acute coronary syndrome in the last 12 months. * Congestive heart failure * Peripheral neuropathy * Previous pelvic radiotherapy * Prior rectal cancer treatment * Pregnancy or nursery * Any contraindications to MRI (e.g. patients with pacemakers) * Indication of pelvic exenteration * Impossibility to consent.

Design outcomes

Primary

MeasureTime frameDescription
Rate of pathological and sustained clinical response3 yearsCombined number of patients with pathological response in the surgical specimen and patients in a Watch and Wait protocol with a sustained clinical response longer than a year.
Quality of Life and Funcional Outcomes3 yearsStandardized evaluation using validated questionnaires comparing patients undergoing TME versus WW patients in the cohort

Secondary

MeasureTime frameDescription
Adverse events3 yearsAdverse events will be graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

Countries

Chile

Contacts

PRINCIPAL_INVESTIGATORFelipe F Quezada-Diaz, MD

Complejo Asistencial Doctor Sótero del Rio

PRINCIPAL_INVESTIGATORNicole M Caire, MD

Complejo Asistencial Doctor Sótero Del Río

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 9, 2026